We remain open and operational during the current COVID-19 pandemic.
FREDERICK, Md., UPDATED on June 6, 2020—
Kemp Proteins is diligently monitoring the threat and impact of COVID-19 on our employees, company, clients, and communities and we define our guidelines on an on-going basis. The situation is rapidly evolving and we are using a risk-based approach to assess the developing situation and will use all sources available to us for review and assessment. Our goal is to keep people safe and preserve business continuity, especially as we work on client directed projects aimed at reagent development and vaccine support for the control of coronavirus infections.
Currently our production personnel are all still attending work but are implementing best PPE practices. We have taken steps to reduce our own exposure by implementing daily cleaning of our facility and training our staff to reduce interaction with team members and other company personnel, effectively social distancing personnel within our own facility.
Kemp Proteins is financially secure to weather this economic downturn. We have no immediate stock shortages and we are taking steps to purchase additional critical supplies so that there is minimal disruption in our own supply chain.
As the situation evolves Kemp Proteins will reach out to discuss impacts with our clients, and how to proceed depending on the stage of the process, but obviously the health and safety of everyone is the most important priority, which will be our guiding principle.
About Kemp Proteins (www.kempproteins.com)
Kemp Proteins (formerly Kempbio) is a leading provider of gene-to-protein bioservices. For more than 20 years, Kemp’s team of protein problem-solvers has delivered best-in-class services that optimize productivity and mitigate risk for life sciences innovators developing protein-based products, including human and veterinary biopharmaceuticals, vaccines, and diagnostics. Our team of protein problem-solvers has provided clients the full-continuum of protein-expression and manufacturing services—from gene to protein. Additionally, our proven hybridoma development specialists provide application-specific, characterized, clonality-assured monoclonal-antibodies. We are focused on delivering timely, high-quality services, data-packages, and products to assist our clients, optimize productivity and mitigate risk in their discovery, development, and manufacturing programs.